Zimmer Biomet (ZBH)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$110.15+13.49%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · ZBH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -11.8% |
| Our one-year growth estimate | diamond | 4.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 15.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers · Company calendar date is not available
ZBH — President transition
Dated 2026-09-08
Group President — Kevin Thornal: The Group President is departing due to a position restructuring with severance benefits, indicating an orderly exit rather than a sudden loss or termination for cause.
Why it matters: Knee sales grew only 0.1% organically in Q2. A stronger result would ease concern about this large product line.
Supportive ifQ3 knee sales grow more than 1% on an organic constant-currency basis.
Worry ifQ3 knee sales are flat or decline on an organic constant-currency basis.
Why it matters: Adjusted EPS was $2.07 in Q2, flat from a year ago. A higher Q3 result would support the raised yearly profit range.
Supportive ifQ3 adjusted diluted EPS is above $2.07, and the company keeps or raises its 2026 range of $8.47 to $8.59.
Worry ifQ3 adjusted diluted EPS is below $2.07, or the company cuts its 2026 adjusted EPS range.
Why it matters: The CFO change is still a key management task. Naming a successor and planning a clear handoff would ease leadership concerns.
Watch forThe company names a CFO successor and gives a clear start date or handoff plan.
Also watch forThe company reports no named successor or a delayed handoff in its next update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$127 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $286 loss on $10,000 · 2.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,246 loss on $10,000 · 22.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.